argenx SE

argenx, based in the Netherlands and listed in Brussels, is a fast-growing immunology biotech built around Vyvgart, a treatment for rare autoimmune diseases such as myasthenia gravis that has become a major commercial success. A promising pipeline aims to extend the same approach to further autoimmune conditions. argenx pays no dividend, reinvesting everything into research and the launch of its medicines, which leaves its score low on a dividend measure. This is a high-growth biotech valued for its expanding drug franchise, not a source of income.